4D pharma Presents Trial in Progress Poster on Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the 2022 American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 05/26/22
4D pharma Presents Late Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International ConferenceBusiness Wire • 05/17/22
4D pharma conference poster underlines safety and potential efficacy of asthma drug candidateProactive Investors • 05/17/22
4D Pharma has a busy year ahead after a successful 12 months of clinical researchProactive Investors • 04/01/22
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022Business Wire • 03/31/22
4D Pharma Shares Soar On MRx0518/Keytruda Combo Trial Data In Renal Cell CarcinomaBenzinga • 03/23/22
4D pharma Announces Positive Interim Results from the Phase I/II Study of the Combination of MRx0518 and KEYTRUDA® (pembrolizumab) for the Treatment of Renal Cell CarcinomaBusiness Wire • 03/23/22
4D pharma sees early success as phase I/II cancer trial hits its efficacy target earlyProactive Investors • 03/23/22
4D pharma to Participate at the Chardan Metagenomics and Microbiome Medicines SummitBusiness Wire • 02/23/22
4D pharma Announces FDA Clearance of IND Application for Live Biotherapeutics MRx0005 and MRx0029 for the Treatment of Parkinson's DiseaseBusiness Wire • 02/22/22
4D pharma receives US regulatory green light for phase I trial of its Parkinson's disease candidatesProactive Investors • 02/22/22
4D Pharma's Asthma Candidate Shows Positive Trends In Multiple Secondary Endpoints Of EfficacyBenzinga • 01/27/22
4D pharma Announces Additional Positive Data From Part A of the Phase I/II Trial Of MRx-4DP0004 For the Treatment of AsthmaBusiness Wire • 01/27/22
4D pharma hails 'highly encouraging' data from its early-stage asthma trialProactive Investors • 01/27/22
4D pharma to Host Virtual KOL Event Discussing Asthma Treatment Landscape and Review of Positive Topline Results from Part A of Phase I/II Trial of MRx-4DP0004Business Wire • 01/20/22